Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 12/20 | 1.00 |
| ▸ | EZH2 | Q15910 | 1/20 | 1.00 |
| ▸ | AHCYL1 | O43865 | 2/20 | 0.65 |
| ▸ | CDA | P32320 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.45 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Deazaneplanocin A SCHEMBL12280736 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL29358420 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL874126 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL13663976 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL12280318 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL18256281 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL12321313 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL1521229 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL863851 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1CDASMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL20595432 | 0.99 | AHCY (0.97) | AHCYEZH2AHCYL1CDASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010508-A1 | COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-01-12 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010508-A1 | COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | EZH2, BMI1, SUZ12 | AHCY 2381/4885EZH2 1/4885AHCYL1 1078/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | AHCY 3736/4885EZH2 2846/4885AHCYL1 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.